Results 81 to 90 of about 926 (182)

Resmetirom: The First Disease‐Specific Treatment for MASH

International Journal of Endocrinology, Volume 2025, Issue 1, 2025.
In 2023, the medical terminology for Nonalcoholic Fatty Liver Disease (NAFLD) and NA SteatoHepatitis (NASH) was updated to Metabolic Dysfunction‐Associated SteatoticLiver Disease (MASLD) and MA SteatoHepatitis (MASH). This review highlights the critical epidemiological, pathophysiological, and therapeutic aspects of MASH, focusing on the novel ...
Ali Mohamed Mousa, Mervat Mahmoud, Ghaida Mubarak AlShuraiaan, Aman Rajpal   +3 more
wiley   +1 more source

Percentage change in triglyceride level following saroglitazar 4 mg treatment.

, 2016
At week 12 saroglitazar treatment led to increase in the C-peptide (percentage change: 59.42, 95% CI: 48.78, 70.06) and fasting insulin levels (percentage change: 47.10; 95% CI: 38.63, 55.57) when compared with baseline; however, it was with in normal ...
Alka Deshpande (847076), Harsh Toshniwal (847077), Shashank Joshi (847078), Rajendrakumar H. Jani (847079)   +3 more
core   +1 more source

Artemether Attenuates High Glucose‐Induced Inflammation and Fibrogenesis in Renal Tubular Epithelial Cells by Modulating the TGF‐β/Smad Pathway Via PPARγ Activation

Journal of Diabetes Research, Volume 2025, Issue 1, 2025.
Artemether (Art) is a derivative of artemisinin, originally sourced from traditional Chinese herbal medicine, with improved bioavailability, and is widely used for malaria treatment. Recently, its potential effects on diabetic complications, particularly diabetic kidney disease (DKD), have attracted increasing attention.
Xiuli Zhang, Lingzhi Li, Rui Xue, Dan Liang, Yue Wang, Weidong Yang, Qinghui Zhou, Zhihong Chi, Mallikarjuna Korivi   +8 more
wiley   +1 more source

Lipid sensing nuclear receptors involved in the pathogenesis of fatty liver disease

FEBS Letters, Volume 598, Issue 23, Page 2854-2855, December 2024.
Non‐alcoholic fatty liver disease (NAFLD) begins with lipid accumulation and progresses toward inflammation and fibrosis. Nuclear receptors (NRs), like the Peroxisome Proliferator‐Activated Receptors alpha and gamma (PPARα and PPARy), the Farnesoid X Receptor (FXR), and the Liver X receptor (LXR), regulate genes by heterodimerizing with Retinoid X ...
Marion Schweiger, Maria Nieves Arredondo‐Lasso, Marika E. Friano, Manuel Gil‐Lozano, Stephan Herzig, Nina Henriette Uhlenhaut   +5 more
wiley   +1 more source

Saroglitazar – A Potential Therapeutic Option in Treating NASH? [Letter]

Drug Design, Development and Therapy, 2021
Syed Hasan Shuja, Farea Eqbal, Hafsa Rehman Dow Medical College, Karachi, Sindh, PakistanCorrespondence: Syed Hasan ShujaDow Medical College, Dow University of Health Sciences, Baba-e-Urdu Road, Karachi, 74200, PakistanTel +923200250770Email hasanshuja6 ...
Shuja SH, Eqbal F, Rehman H
doaj  

A randomized comparative study of efficacy and safety of saroglitazar with fenofibrate in diabetic dyslipidemic patients on metformin and glimeperide

, 2017
Background: This study was conducted to compare the efficacy and safety of saroglitazar with fenofibrate in Indian diabetic dyslipidemic patients who were on Metformin and Glimepiride.Methods: Adults patients with diabetic dyslipidaemia fulfilling the ...
Momin Mohd. Abdul Mujeeb, Ahmed, Syed Mohsin, Syed Mohsin Ahmed, Mujeeb, Momin Mohd. Abdul   +3 more
core   +2 more sources

Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists

, 2020
<p>Non-alcoholic steatohepatitis (NASH) is a highly prevalent, chronic liver disease characterized by hepatic lipid accumulation, inflammation, and concomitant fibrosis. Up to date, no anti-NASH drugs have been approved.
Vera Rogiers, Joost Boeckmans, Robim M Rodrigues, Karolien Buyl, Tamara Vanhaecke, Joery De Kock, Alessandra Natale, Veerle De Boe, Anja Heymans, Matthias Rombaut, Brent Cami   +10 more
core   +1 more source

Comparative Efficacy of Saroglitazar and Pioglitazone in Nonalcoholic Fatty Liver Disease Patients: A Bayesian Network Meta-analysis

International Journal of Diabetes and Technology
Background and Aims: Nonalcoholic fatty liver disease (NAFLD) is associated with metabolic syndrome. Two drugs, saroglitazar (S) and pioglitazone (P), are known to have beneficial effects on metabolic syndrome.
Binayak Sinha, Samit Ghosal, Debasis Datta   +2 more
doaj   +1 more source

STABILITY INDICATING METHOD DEVELOPMENT AND VALIDATION OF SAROGLITAZAR IN BULK AND PHARMACEUTICAL DOSAGE FORM BY REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

, 2019
A simple, Précised, Accurate method was developed for the estimation of Saroglitazar by RP-HPLC technique. Chromatographic conditions used were stationary phase BDS100mm x 4.6 mm, 5., Mobile phase water: Acetonitrile in the ratio of 45:55 and flow rate ...
Kasukurthi Rama Devi*, P. Prachet, Rama Rao Nadendla
core   +1 more source

The nuances of atherogenic dyslipidemia in diabetes: Focus on triglycerides and current management strategies

Indian Heart Journal, 2013
Diabetes mellitus (DM) is a pandemic disease and an important cardiovascular (CV) risk factor. The atherogenic dyslipidemia in diabetes (ADD) is characterized by high serum triglycerides, high small dense LDL levels, low HDL levels and postprandial ...
P.C. Manoria, H.K. Chopra, S.K. Parashar, A.L. Dutta, Brian Pinto, Ajit Mullasari, Samir Prajapati   +6 more
doaj   +1 more source